Rifampin isoniazid indications and usage: Difference between revisions
No edit summary |
No edit summary |
||
| Line 3: | Line 3: | ||
{{CMG}}; {{AE}} {{chetan}} | {{CMG}}; {{AE}} {{chetan}} | ||
== | ==Indications And Usage== | ||
For pulmonary tuberculosis in which organisms are susceptible, and when the patient has been titrated on the individual components and it has therefore been established that this fixed dosage is therapeutically effective. | For pulmonary tuberculosis in which organisms are susceptible, and when the patient has been titrated on the individual components and it has therefore been established that this fixed dosage is therapeutically effective. | ||
| Line 11: | Line 11: | ||
In the treatment of tuberculosis, small numbers of resistant cells, present within large populations of susceptible cells, can rapidly become the predominating type. Since rapid emergence of resistance can occur, culture and susceptibility tests should be performed in the event of persistent positive cultures. | In the treatment of tuberculosis, small numbers of resistant cells, present within large populations of susceptible cells, can rapidly become the predominating type. Since rapid emergence of resistance can occur, culture and susceptibility tests should be performed in the event of persistent positive cultures. | ||
This drug is not indicated for the treatment of [[meningococcal]] infections or asymptomatic carriers of [[N. meningitidis]] to eliminate meningococci from the nasopharynx. | This drug is not indicated for the treatment of [[meningococcal]] infections or asymptomatic carriers of [[N. meningitidis]] to eliminate meningococci from the nasopharynx.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = RIFAMATE (RIFAMPIN AND ISONIAZID) CAPSULE [SANOFI-AVENTIS U.S. LLC] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3cc36609-8e2d-4caa-a8e0-c0367e3e52df | publisher = | date = | accessdate }}</ref> | ||
<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = RIFAMATE (RIFAMPIN AND ISONIAZID) CAPSULE [SANOFI-AVENTIS U.S. LLC] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3cc36609-8e2d-4caa-a8e0-c0367e3e52df | publisher = | date = | accessdate }}</ref> | |||
==References== | ==References== | ||
Latest revision as of 02:54, 5 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Chetan Lokhande, M.B.B.S [2]
Indications And Usage
For pulmonary tuberculosis in which organisms are susceptible, and when the patient has been titrated on the individual components and it has therefore been established that this fixed dosage is therapeutically effective.
This fixed-dosage combination drug is not recommended for initial therapy of tuberculosis or for preventive therapy.
In the treatment of tuberculosis, small numbers of resistant cells, present within large populations of susceptible cells, can rapidly become the predominating type. Since rapid emergence of resistance can occur, culture and susceptibility tests should be performed in the event of persistent positive cultures.
This drug is not indicated for the treatment of meningococcal infections or asymptomatic carriers of N. meningitidis to eliminate meningococci from the nasopharynx.[1]
References
- ↑ "RIFAMATE (RIFAMPIN AND ISONIAZID) CAPSULE [SANOFI-AVENTIS U.S. LLC]". Text " accessdate " ignored (help)
Adapted from the FDA Package Insert.